Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing&nb...
PacBio , a leading developer of high-quality, highly accurate sequencing solutions, announced the signing of a new Research Collaboration Agre...
Aileron Therapeutics, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs i...
Simultaneously and reliably quantify proteins, including post-translational modifications (PTMs), in a single-cell RNA sequencing (RNA-seq) assay using...
NovaCina, a global contract development and manufacturing organization (CDMO), has today announced the expansion of its facility in Perth, Australia with...
Organizations Plan to Jointly Advance Breakthrough Solutions in Human Health and Sustainability, Drive Research Collaboration, Entrepreneurship and Acceler...
In a year when metabolic diseases have drawn major investor interest, the newest player has big-name backing, a sizable war chest and veteran leadership. ...
Thryv Therapeutics, a clinical stage biotech company dedicated to developing treatments for rare and life-threatening cardiovascular indications, announced...
This ADHD Awareness Month, we stand with the ADHD community. Alora Pharmaceuticals, LLC, the largest U.S. manufacturer of methylphenidate medications,...
Thermo Fisher Scientific Inc., the world leader in serving science, announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD)...
On the eve of the International Myeloma Society (IMS) Annual Meeting, Dr. Yongke Zhang, Chief Scientific Officer of IASO Biotherapeutics (IASO Bio), along ...
The company's intellectual property ("IP") covers the formulation and method of use of polihexanide in the treatment of acanthamoeba keratitis and fung...
Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death1 Phase ...
Reported cumulative MMR rate of 44% by 24 weeks, with stable or deepening responses between weeks 12 and 24, continuing to surpass prior Phase 1 trials o...
© 2024 Biopharma Boardroom. All Rights Reserved.
